TeV-Scale Z' Bosons from D-branes

Generic D-brane string models of particle physics predict the existence of extra U(1) gauge symmetries beyond hypercharge. These symmetries are not of the E_6 class but rather include the gauging of Baryon and Lepton numbers as well as certain Peccei-Quinn-like symmetries. Some of the U(1)'s have triangle anomalies, but they are cancelled by a Green-Schwarz mechanism. The corresponding gauge bosons typically acquire a mass of order the string scale M_S by combining with two-index antisymmetric fields coming from the closed string sector of the theory. We argue that in string models with a low string scale M_S proportional to 1-10 TeV, the presence of these generic U(1)'s may be amenable to experimental test. Present constraints from electroweak precision data already set important bounds on the mass of these extra gauge bosons. In particular, for large classes of models, rho-parameter constraints imply M_S >= 1.5 TeV. In the present scheme some fraction of the experimentally measured Z^0 mass would be due not to the Higgs mechanism, but rather to the mixing with these closed string fields. We give explicit formulae for recently constructed classes of intersecting D6- and D5-brane models yielding the Standard Model (SM) fermion spectrum.Comment: 46 pages, LaTeX, JHEP.cls, 21 Figures. minor correction

Defining and measuring “eczema control”: An international qualitative study to explore the views of those living with and treating atopic eczema

Background Atopic eczema (also known as eczema) is a chronic, inflammatory skin condition that often afflicts patients’ health and wellbeing. The Harmonising Outcome Measures for Eczema (HOME) initiative recommends that “long-term control of eczema” is measured in all clinical trials 3 months or longer in duration. However, little has been published on what eczema control means to those living with or treating atopic eczema. Objectives To i) develop understanding of what eczema control means to patients, carers and clinicians and ii) explore the feasibility and acceptability of different ways of measuring eczema control in the long-term. Methods Online focus groups explored patients/carers experiences in the UK, USA, the Netherlands, France, Sweden and Japan, and an international online survey gathered views of clinicians. The Framework Method was used to analyse the focus groups and thematic analysis was used to analyse survey data. All findings were integrated into a theoretical framework to create overarching themes that cut across these diverse groups. Results Eight focus groups with patients (16 years+) and eight groups with carers of children took place (N=97). Sixty-two people took part in the survey. Eczema control was described as a multifaceted construct involving changes in disease activity, the treatment and management of the condition, and psychological, social and physical functioning. Patient /carer measurement allows personal accounts and frequent measurement, whilst clinician measurement was deemed less subjective. The burden on patients/carers and issues for analysing and interpreting data should be considered. Conclusions This study formed the basis of judging the content validity and feasibility of measurement instruments/methods to assess control of eczema in clinical trials. This online approach to an international qualitative study is an example of how core outcome set developers with limited resources can engage with multiple stakeholder groups on an international basis to inform consensus meeting discussions

Constraints on Dark Matter Annihilation in Clusters of Galaxies with the Fermi Large Area Telescope

Nearby clusters and groups of galaxies are potentially bright sources of high-energy gamma-ray emission resulting from the pair-annihilation of dark matter particles. However, no significant gamma-ray emission has been detected so far from clusters in the first 11 months of observations with the Fermi Large Area Telescope. We interpret this non-detection in terms of constraints on dark matter particle properties. In particular for leptonic annihilation final states and particle masses greater than ~200 GeV, gamma-ray emission from inverse Compton scattering of CMB photons is expected to dominate the dark matter annihilation signal from clusters, and our gamma-ray limits exclude large regions of the parameter space that would give a good fit to the recent anomalous Pamela and Fermi-LAT electron-positron measurements. We also present constraints on the annihilation of more standard dark matter candidates, such as the lightest neutralino of supersymmetric models. The constraints are particularly strong when including the fact that clusters are known to contain substructure at least on galaxy scales, increasing the expected gamma-ray flux by a factor of ~5 over a smooth-halo assumption. We also explore the effect of uncertainties in cluster dark matter density profiles, finding a systematic uncertainty in the constraints of roughly a factor of two, but similar overall conclusions. In this work, we focus on deriving limits on dark matter models; a more general consideration of the Fermi-LAT data on clusters and clusters as gamma-ray sources is forthcoming.Comment: accepted to JCAP, Corresponding authors: T.E. Jeltema and S. Profumo, minor revisions to be consistent with accepted versio

Observation of B+ -> K+ eta gamma

We report measurements of radiative B decays with K eta gamma final states, using a data sample of 253 /fb recorded at the Upsilon(4S) resonance with the Belle detector at the KEKB e+e- storage ring. We observe B+ -> K+ eta gamma for the first time with a branching fraction of (8.4 +- 1.5(stat) +1.2 -0.9(syst)) X 10^{-6} for M(Keta) K0 eta gamma. We also search for B -> K3*(1780) gamma.Comment: 12 pages, 5 figures, accepted by Phys. Lett.

Study of B0ˉ→D(∗)0π+π−\bar{B^{0}} \to D^{(*)0} \pi^+ \pi^- Decays

We report on a study of $\bar{B^{0}} \to D^{(*) 0} \pi^+ \pi^-$ decays using 29.1 fb$^{-1}$ of $e^{+}e^{-}$ annihilation data recorded at the $\Upsilon(4S)$ resonance with the Belle detector at the KEKB storage ring. Making no assumptions about the intermediate mechanism, the branching fractions for $\bar{B}^0 \to D^0 \pi^+ \pi^-$ and $\bar{B}^0 \to D^{* 0} \pi^+ \pi^-$ are determined to be $(8.0 \pm 0.6 \pm 1.5) \times 10^{-4}$ and $(6.2 \pm 1.2 \pm 1.8) \times 10^{-4}$ respectively. An analysis of $\bar{B^{0}} \to D^{0} \pi^+ \pi^-$ candidates yields to the first observation of the color-suppressed hadronic decay $\bar{B}^0 \to D^0 \rho^0$ with the branching fraction $(2.9 \pm 1.0 \pm 0.4) \times 10^{-4}$. We measure the ratio of branching fractions ${\mathcal B}(\bar{B^0} \to D^0 \rho^0) / {\mathcal B}(\bar{B^0} \to D^0 \omega)$ = 1.6 $\pm$ 0.8.Comment: 13 pages, LaTex, 4 figures, submitted to Phys. Lett.

Measurements of Branching Fractions and Decay Amplitudes in B-> J/\psi K^* decays

The branching fractions and the decay amplitudes of B -> J/psi K^* decays are measured in a 29.4/fb data sample collected with the Belle detector at the KEKB electron-positron collider. The decay amplitudes of helicity states of the J/psi K^* system are determined from the full angular distribution of the final state particles in the transversity basis. The branching fractions are measured to be (1.29\pm0.05\pm0.13) \times 10^{-3} for neutral mesons and (1.28\pm0.07\pm0.14) \times 10^{-3} for charged mesons. The measured longitudinal and transverse (perpendicular to the transversity plane) amplitudes are |A_0|^2 = 0.62\pm0.02\pm0.03 and |A_{\perp}|^2 = 0.19\pm0.02\pm0.03, respectively. The value of |A_{\perp}|^2 shows that the CP even component dominates in the B^0 \to J/\psi K^{*0}(K_S\pi^0) decay.Comment: 17 pages, 3 figures, 5 tables, to appear in Phys. Lett.

Measurement of the inclusive semileptonic branching fraction of B mesons and |Vcb|

We present a measurement of the electron spectrum from inclusive semileptonic {\it B} decay, using 5.1 fb$^{-1}$ of $\Upsilon(4S)$ data collected with the Belle detector. A high-momentum lepton tag was used to separate the semileptonic {\it B} decay electrons from secondary decay electrons. We obtained the branching fraction, ${\cal B}(B\to X e^+ \nu) = (10.90 \pm 0.12 \pm 0.49)$, with minimal model dependence. From this measurement, we derive a value for the Cabibbo-Kobayashi-Maskawa matrix element $|V_{cb}| = 0.0408 \pm 0.0010 {\rm (exp)} \pm 0.0025{\rm (th)}$.Comment: 16 pages, 3 figures, 3 table

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12–14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Moderated whole-group and small-group consensus discussions were informed by presentations of qualitative studies, systematic reviews and validation studies. Small-group allocations were performed a priori to ensure that each group included different stakeholders from a variety of geographical regions. Anonymous whole-group voting was carried out using handheld electronic voting pads according to predefined consensus rules. It was agreed by consensus that the long-term control domain should include signs, symptoms, quality of life and a patient global instrument. The group agreed that itch intensity should be measured when assessing long-term control of eczema in addition to the frequency of itch captured by the symptoms domain. There was no recommendation of an instrument for the core outcome domain of quality of life in children, but existing instruments were assessed for face validity and feasibility, and future work that will facilitate the recommendation of an instrument was agreed upon. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international group working together to develop a core outcome set (COS) for clinical trials in eczema (synonymous with atopic eczema and atopic dermatitis). HOME is coordinated from the Centre of Evidence Based Dermatology, University of Nottingham, U.K. Participation in HOME is open to anyone with an interest in outcomes for eczema. A COS is the agreed upon minimum set of instruments that should be included in all clinical trials for a particular condition. Use of a COS does not preclude using other instruments; other domains and instruments can also be included to meet the specific requirements of individual trials. COS initiatives are active across many fields of medicine and should enable better synthesis of trial data and reduce selective outcome reporting bias. The HOME initiative follows the best current guidance on developing a COS. Four core domains have been identified: clinician-reported signs; patient-reported symptoms; quality of life; and long-term control. The core outcome measurement instruments for clinician-reported signs and patient-reported symptoms have been established: the Eczema Area and Severity Index (EASI) for measuring clinician reported signs was agreed on at the HOME III meeting, and the Patient-Oriented Eczema Measure (POEM) was chosen to measure patient-reported symptoms at the HOME IV meeting. This is a report from the fifth consensus meeting of the HOME initiative (HOME V), which was held on 12–14 June 2017 in Nantes, France. The local organizers were Sebastien Barbarot and Jean-Francois Stalder of Nantes University Hospital, France

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms